SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor

Abstract

Taken together, these data suggest that SB265610 behaves as an allosteric inverse agonist at the CXCR2 receptor, binding at a region distinct from the agonist binding site to prevent receptor activation, possibly by interfering with G protein coupling.